Bioequivalence of LANIDIEM® Tablet 4 mg to Vaxar® Tablet 4 mg(Lacidipine 4 mg)
![]() |
Lee, Yun-Young
(Department of Drug Development Service, BioCore Co., Ltd.)
Kim, Hye-Jin (Department of Drug Development Service, BioCore Co., Ltd.) La, Sookie (Department of Drug Development Service, BioCore Co., Ltd.) Cho, Kyung-Hee (Department of Drug Development Service, BioCore Co., Ltd.) Jang, Moon-Sun (Department of Drug Development Service, BioCore Co., Ltd.) Park, Young-Joon (Samil Pharm. Co., Ltd.) Lee, Hee-Joo (Department of Drug Development Service, BioCore Co., Ltd.) |
1 | N.V.S. Ramakrishna, K.N. Vishwottam, S. Puran, S. Manoj, M. Santosh and M. Koteshwara, Simple, sensitive and rapid liquid chromatographic/ electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma, J. Mass Spectrom., 39, 824-832 (2004). DOI |
2 | ICH guideline; Validation of analytical procedures: Methodology (1996). |
3 | P. Tcherdakoff and the Investigators of Study LAC-05-91, French large-scale study evaluating the tolerability and efficacy of lacidipine, J. Cardiovasc. Pharmacol., 25, S27-S32 (1995). DOI |
4 | P.L. McCormack and A. J. Wagstaff, Lacidipine: a review of its use in the management of hypertension, Drugs, 63, 2327-2356 (2003). DOI |
5 | L. Squassante, E. Caveggion, S. Braggio, M. Pellegatti and P. Baroldi, A study of plasma disposition kinetics of lacidipine after single oral ascending doses, J. Cardiovasc. Pharmacol., 23, S94-S97 (1994) DOI |
6 | L. Da Ros, L. Squassante and S. Milleri, Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers, Clin. Pharmacokinet., 42, 99-106 (2003). DOI |
7 | J. Tang, R. Zhu, R. Zhao, G. Cheng and W. Peng, Ultraperformance liquid chromatography-tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study, J. Pharm. Biomed. Anal., 47, 923-928 (2008). DOI |
8 | 식품의약품안전청 고시 제 2005-31호, 생물학적동등성시험기준 (2005. 06. 07). |
![]() |